The global DNA manufacturing market was valued at USD 5.65 billion in 2024 and is projected to reach USD 14.96 billion by 2030, expanding at a Compound Annual Growth Rate (CAGR) of 18.10% from 2025 to 2030. This robust market growth is primarily driven by the rising demand for gene therapies, which are revolutionizing treatment approaches for genetic disorders and rare diseases. Additionally, personalized medicine, which tailors medical treatment to individual genetic profiles, is further boosting demand for high-quality, customized DNA materials. Simultaneously, advancements in synthetic biology a field that involves designing and constructing new biological parts or systems are opening new avenues for DNA applications, contributing significantly to market growth.

The market is also benefitting from the expanding use of DNA technologies in pharmaceutical research and vaccine development. As a notable example, in July 2024, GenScript Biotech introduced a cutting-edge DNA synthesis platform that significantly reduces production timelines. This innovation supports faster development of gene therapies and synthetic vaccines, aligning with the increasing need for rapid and efficient genetic material production. Furthermore, favorable government initiatives, coupled with rising public and private sector investments in genomics and biotechnology, are expected to accelerate further growth in the DNA manufacturing market.

Key Market Trends & Insights:

• North America emerged as the dominant regional market in 2024, accounting for the largest revenue share of 46.23%. This dominance is attributed to a mature biotechnology sector, strong government support, a high number of research institutions, and a well-established regulatory framework.
• The Asia-Pacific region is anticipated to witness the fastest CAGR of 19.03% during the forecast period. The region’s rapid growth is being propelled by increased investments in biotech infrastructure, a growing pool of skilled professionals, and expanding clinical research activities in countries like China, India, and South Korea.
• The synthetic DNA segment led the market in 2024 by capturing the largest revenue share. This is due to its widespread use in research, diagnostics, and therapeutics. The plasmid DNA manufacturing segment, crucial for gene therapy and vaccine production, is expected to grow at the fastest CAGR throughout the forecast period.
• GMP-grade DNA manufacturing (Good Manufacturing Practice-compliant) dominated the market in 2024, owing to its essential role in clinical and commercial therapeutic applications. Meanwhile, R&D-grade DNA manufacturing is projected to grow at a significant CAGR, driven by its extensive use in preclinical research and academic settings.
• The cell and gene therapy (CGT) segment held the largest revenue share in 2024. The growing pipeline of gene therapies and CAR-T cell therapies continues to boost demand for high-quality DNA manufacturing services. The oligonucleotide-based drugs segment is anticipated to register the fastest CAGR of 20.9% during the forecast period.
• The pharmaceutical and biotechnology companies segment was the largest contributor to market revenue in 2024, with a share of 48.68%. This reflects the critical role of DNA materials in drug discovery, development, and biomanufacturing. The Contract Research Organizations (CROs) segment is expected to experience the fastest CAGR, driven by the increasing trend of outsourcing DNA synthesis and manufacturing services to improve operational efficiency and reduce time-to-market.

Order a free sample PDF of the DNA Manufacturing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2024 Market Size: USD 5.65 Billion
• 2030 Projected Market Size: USD 14.96 Billion
• CAGR (2025-2030): 18.10%
• North America: Largest market in 2024
• Asia Pacific: Fastest growing market

Key Companies & Market Share Insights:

The DNA manufacturing market is highly competitive, characterized by the presence of several leading players who have established dominance through advanced product offerings, extensive R&D investments, and strategic collaborations.

• Companies such as Charles River Laboratories, VGXI, Inc., Danaher (through its subsidiary Aldevron), and Thermo Fisher Scientific hold significant market share. Their comprehensive service portfolios, global manufacturing capacities, and focus on compliance with regulatory standards allow them to serve a diverse client base, ranging from research institutions to commercial biopharma firms.
• Organizations like Lonza, Charles River Laboratories, Thermo Fisher Scientific, and VGXI, Inc. continue to lead through the deployment of cutting-edge technologies, end-to-end service offerings, and targeted growth initiatives. Their leadership is further reinforced by their responsiveness to increasing demand for high-purity plasmid DNA and other genetic materials used in cell and gene therapies, vaccines, and other biopharmaceuticals.
• Firms such as GenScript, Catalent, and Wuxi AppTec are aggressively expanding their market presence via strategic investments, expansion of manufacturing facilities, and acquisitions. These moves aim to enhance their capabilities and geographical reach, enabling them to meet the growing needs of clients globally.
• Companies like Charles River Laboratories, VGXI, Inc., and Lonza are at the forefront of offering advanced contract development and manufacturing organization (CDMO) services. These players provide a full spectrum of solutions including preclinical research, process development, and large-scale DNA manufacturing, playing an instrumental role in bringing novel gene therapies and biologics to market faster.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The DNA manufacturing market is undergoing a dynamic transformation, marked by a synergy between established industry expertise and innovative startups. The competitive landscape is being reshaped by an uptick in mergers and acquisitions, strategic partnerships, and breakthrough product launches. Companies that can effectively merge scientific rigor with market-oriented innovation are expected to gain a competitive edge and deliver long-term value. As the demand for precision health solutions continues to rise, factors such as accessibility, cost-effectiveness, and ethical sourcing of genetic materials will become increasingly pivotal in shaping the future trajectory of the market.